What does it take to develop new antibiotics and ensure they reach the patients who need them most?
In 2025, GARDP reached important milestones in the fight against antimicrobial resistance (AMR),...
What does it take to develop new antibiotics and ensure they reach the patients who need them most?
In 2025, GARDP reached important milestones in the fight against antimicrobial resistance (AMR),...
Pooled procurement
Susana Ribeiro, GARDP (Switzerland)
Read the definitions on the REVIVE Antimicrobial Encyclopaedia here:
https://revive.gardp.org/resource/pooled-procurement/?cf=encyclopaedia
Natural product-inspired antibiotics: Successes and future prospects
Speakers:
Mark Butler, Director, MSBChem Consulting and University of Queensland (Australia)
Christine Beemelmanns, Head of the...
For three weeks, baby Francis was treated for neonatal sepsis. His story reflects a challenge faced by hospitals around the world as drug-resistant infections threaten the lives of newborns.
In th...
Current developments in Clostridioides difficile prevention, therapy and R&D
This REVIVE webinar was done in collaboration with the Peggy Lillis Foundation.
Speakers:
Benedikt Huttner, Unit Head
For many women in science, turning curiosity into impact requires persistence, and the opportunity to lead.
On the International Day of Women and Girls in Science, GARDP highlights the vital role ...
🎗️ United by Unique. Threatened by AMR.
For people with cancer, infections are already a leading cause of death. As antimicrobial resistance grows, even routine infections are becoming harder, and..
GARDP Webinar, broadcast on 15 January 2026
In 2019, GARDP launched “5 BY 25”, an initiative to develop five new antibiotic treatments during the period 2020-2025. Part of a broader strategy, 5 B...
This video highlights GARDP’s key achievements in 2025 and shows how our not-for-profit R&D model is advancing the development and delivery of urgently needed antibiotics. Together we are demonstr
Public-private partnership (PPP)
Clara Maure, GARDP (Switzerland)
Read the definitions on the REVIVE Antimicrobial Encyclopaedia here:
https://revive.gardp.org/resource/public-private-partnership-...
This webinar explores the scientific challenges in antibiotic discovery, the role of shared data in overcoming these challenges, and how AntibioticDB serves as a practical tool to accelerate resear...
Japan is an essential partner in GARDP’s mission to tackle antimicrobial resistance.
With the support of the Japanese government and the Ministry of Health, Labour and Welfare (MHLW), GARDP is work...
💡 The AMR research world is facing a worrying knowledge gap. Fewer young scientists are entering the field and critical expertise from past decades is not being passed on. This fragmentation is slo..
🧬 The global antibiotic pipeline is alarmingly thin.
Today, only around 90 antibiotics are in development worldwide and fewer than 15 are considered truly innovative.
Resistance is rising faster t..
🌍 Over 50 million deaths could be prevented by 2050 if people had access to effective antibiotics.
But in many low- and middle-income countries, fewer than 1 in 15 patients with drug-resistant inf..
👶 Every year, 3 million newborns are affected by sepsis — one of the leading causes of death in this vulnerable age group.
To mark World Children’s Day, Carol Ruffell shares how GARDP is respondin..
Every day, more than 1 million curable STIs are acquired, and gonorrhoea is becoming harder to treat.
In some countries, even ceftriaxone, the last recommended treatment, is beginning to fail.
In...
Serious bacterial infections (SBIs) kill 7.7 million people each year.
They’re spreading faster than new antibiotics can be developed, putting lives at risk around the world.
As we mark World AMR ...
Speakers:
Adrian Egli, Director, Institute of Medical Microbiology, University of Zürich (Switzerland)
Javier Fernández Domínguez, co-founder and co-CEO, Pragmatech AI Solutions (Spain)
Moderator:...